We provide proof-of-principle analysis showing that one of these novel targets, Cystatin C (CST3) is a functionally relevant CIRBP target in breast cancer, as depletion of CST3 abrogates the deleterious effects of CIRBP depletion. This evidence concerns the gene CST3 and breast carcinoma.